Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 98

1.

Integrating access to care and tumor patterns by race and age in the Carolina Breast Cancer Study, 2008-2013.

Emerson MA, Golightly YM, Tan X, Aiello AE, Reeder-Hayes KE, Olshan AF, Earp HS, Troester MA.

Cancer Causes Control. 2020 Mar;31(3):221-230. doi: 10.1007/s10552-019-01265-0. Epub 2020 Jan 16.

PMID:
31950321
2.

Interaction between androgen receptor and coregulator SLIRP is regulated by Ack1 tyrosine kinase and androgen.

De Silva D, Zhang Z, Liu Y, Parker JS, Xu C, Cai L, Wang GG, Earp HS, Whang YE.

Sci Rep. 2019 Dec 9;9(1):18637. doi: 10.1038/s41598-019-55057-2.

3.

The role of endothelial MERTK during the inflammatory response in lungs.

Li Y, Wittchen ES, Monaghan-Benson E, Hahn C, Earp HS, Doerschuk CM, Burridge K.

PLoS One. 2019 Dec 5;14(12):e0225051. doi: 10.1371/journal.pone.0225051. eCollection 2019.

4.

Assessment of interactions between 205 breast cancer susceptibility loci and 13 established risk factors in relation to breast cancer risk, in the Breast Cancer Association Consortium.

Kapoor PM, Lindström S, Behrens S, Wang X, Michailidou K, Bolla MK, Wang Q, Dennis J, Dunning AM, Pharoah PDP, Schmidt MK, Kraft P, García-Closas M, Easton DF, Milne RL, Chang-Claude J; Breast Cancer Association Consortium .

Int J Epidemiol. 2019 Oct 12. pii: dyz193. doi: 10.1093/ije/dyz193. [Epub ahead of print]

5.

Bimodal age distribution at diagnosis in breast cancer persists across molecular and genomic classifications.

Allott EH, Shan Y, Chen M, Sun X, Garcia-Recio S, Kirk EL, Olshan AF, Geradts J, Earp HS, Carey LA, Perou CM, Pfeiffer RM, Anderson WF, Troester MA.

Breast Cancer Res Treat. 2020 Jan;179(1):185-195. doi: 10.1007/s10549-019-05442-2. Epub 2019 Sep 18.

6.

Data-Driven Construction of Antitumor Agents with Controlled Polypharmacology.

Da C, Zhang D, Stashko M, Vasileiadi E, Parker RE, Minson KA, Huey MG, Huelse JM, Hunter D, Gilbert TSK, Norris-Drouin J, Miley M, Herring LE, Graves LM, DeRyckere D, Earp HS, Graham DK, Frye SV, Wang X, Kireev D.

J Am Chem Soc. 2019 Oct 2;141(39):15700-15709. doi: 10.1021/jacs.9b08660. Epub 2019 Sep 20.

PMID:
31497954
7.

TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma.

Holtzhausen A, Harris W, Ubil E, Hunter DM, Zhao J, Zhang Y, Zhang D, Liu Q, Wang X, Graham DK, Frye SV, Earp HS.

Cancer Immunol Res. 2019 Oct;7(10):1672-1686. doi: 10.1158/2326-6066.CIR-19-0008. Epub 2019 Aug 26.

PMID:
31451482
8.

Kinome profiling of non-Hodgkin lymphoma identifies Tyro3 as a therapeutic target in primary effusion lymphoma.

Wong JP, Stuhlmiller TJ, Giffin LC, Lin C, Bigi R, Zhao J, Zhang W, Bravo Cruz AG, Park SI, Earp HS, Dittmer DP, Frye SV, Wang X, Johnson GL, Damania B.

Proc Natl Acad Sci U S A. 2019 Aug 13;116(33):16541-16550. doi: 10.1073/pnas.1903991116. Epub 2019 Jul 25.

9.

Beyond growth signaling: apoptotic sensor MERTK activates AKT by a novel mechanism.

Zhang Y, Earp HS, Liu P.

Mol Cell Oncol. 2019 May 7;6(4):1611161. doi: 10.1080/23723556.2019.1611161. eCollection 2019.

PMID:
31211243
10.

MERTK mediated novel site Akt phosphorylation alleviates SAV1 suppression.

Jiang Y, Zhang Y, Leung JY, Fan C, Popov KI, Su S, Qian J, Wang X, Holtzhausen A, Ubil E, Xiang Y, Davis I, Dokholyan NV, Wu G, Perou CM, Kim WY, Earp HS, Liu P.

Nat Commun. 2019 Apr 3;10(1):1515. doi: 10.1038/s41467-019-09233-7.

11.

SGC-GAK-1: A Chemical Probe for Cyclin G Associated Kinase (GAK).

Asquith CRM, Berger BT, Wan J, Bennett JM, Capuzzi SJ, Crona DJ, Drewry DH, East MP, Elkins JM, Fedorov O, Godoi PH, Hunter DM, Knapp S, Müller S, Torrice CD, Wells CI, Earp HS, Willson TM, Zuercher WJ.

J Med Chem. 2019 Mar 14;62(5):2830-2836. doi: 10.1021/acs.jmedchem.8b01213. Epub 2019 Feb 26.

12.

The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma.

Zhao X, Little P, Hoyle AP, Pegna GJ, Hayward MC, Ivanova A, Parker JS, Marron DL, Soloway MG, Jo H, Salazar AH, Papakonstantinou MP, Bouchard DM, Jefferys SR, Hoadley KA, Ollila DW, Frank JS, Thomas NE, Googe PB, Ezzell AJ, Collichio FA, Lee CB, Earp HS, Sharpless NE, Hugo W, Wilmott JS, Quek C, Waddell N, Johansson PA, Thompson JF, Hayward NK, Mann GJ, Lo RS, Johnson DB, Scolyer RA, Hayes DN, Moschos SJ.

Front Oncol. 2019 Jan 4;8:584. doi: 10.3389/fonc.2018.00584. eCollection 2018.

13.

Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma.

Sinik L, Minson KA, Tentler JJ, Carrico J, Bagby SM, Robinson WA, Kami R, Burstyn-Cohen T, Eckhardt SG, Wang X, Frye SV, Earp HS, DeRyckere D, Graham DK.

Mol Cancer Ther. 2019 Feb;18(2):278-288. doi: 10.1158/1535-7163.MCT-18-0456. Epub 2018 Nov 27.

14.

MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity.

Lee-Sherick AB, Jacobsen KM, Henry CJ, Huey MG, Parker RE, Page LS, Hill AA, Wang X, Frye SV, Earp HS, Jordan CT, DeRyckere D, Graham DK.

JCI Insight. 2018 Nov 2;3(21). pii: 97941. doi: 10.1172/jci.insight.97941.

15.

Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis.

Shu X, Wu L, Khankari NK, Shu XO, Wang TJ, Michailidou K, Bolla MK, Wang Q, Dennis J, Milne RL, Schmidt MK, Pharoah PDP, Andrulis IL, Hunter DJ, Simard J, Easton DF, Zheng W; Breast Cancer Association Consortium.

Int J Epidemiol. 2019 Jun 1;48(3):795-806. doi: 10.1093/ije/dyy201.

16.

ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer.

Cai L, Tsai YH, Wang P, Wang J, Li D, Fan H, Zhao Y, Bareja R, Lu R, Wilson EM, Sboner A, Whang YE, Zheng D, Parker JS, Earp HS, Wang GG.

Mol Cell. 2018 Oct 18;72(2):341-354.e6. doi: 10.1016/j.molcel.2018.08.029. Epub 2018 Sep 27.

17.

MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type EGFR Family Members.

Yan D, Parker RE, Wang X, Frye SV, Earp HS 3rd, DeRyckere D, Graham DK.

Clin Cancer Res. 2018 Dec 15;24(24):6523-6535. doi: 10.1158/1078-0432.CCR-18-0040. Epub 2018 Sep 7.

18.

MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.

McDaniel NK, Cummings CT, Iida M, Hülse J, Pearson HE, Vasileiadi E, Parker RE, Orbuch RA, Ondracek OJ, Welke NB, Kang GH, Davies KD, Wang X, Frye SV, Earp HS, Harari PM, Kimple RJ, DeRyckere D, Graham DK, Wheeler DL.

Mol Cancer Ther. 2018 Nov;17(11):2297-2308. doi: 10.1158/1535-7163.MCT-17-1239. Epub 2018 Aug 9.

19.

Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing Assays.

Coombs CC, Gillis NK, Tan X, Berg JS, Ball M, Balasis ME, Montgomery ND, Bolton KL, Parker JS, Mesa TE, Yoder SJ, Hayward MC, Patel NM, Richards KL, Walko CM, Knepper TC, Soper JT, Weiss J, Grilley-Olson JE, Kim WY, Earp HS 3rd, Levine RL, Papaemmanuil E, Zehir A, Hayes DN, Padron E.

Clin Cancer Res. 2018 Dec 1;24(23):5918-5924. doi: 10.1158/1078-0432.CCR-18-1201. Epub 2018 Jun 4.

20.

Factor XIIIA-expressing inflammatory monocytes promote lung squamous cancer through fibrin cross-linking.

Porrello A, Leslie PL, Harrison EB, Gorentla BK, Kattula S, Ghosh SK, Azam SH, Holtzhausen A, Chao YL, Hayward MC, Waugh TA, Bae S, Godfrey V, Randell SH, Oderup C, Makowski L, Weiss J, Wilkerson MD, Hayes DN, Earp HS, Baldwin AS, Wolberg AS, Pecot CV.

Nat Commun. 2018 May 18;9(1):1988. doi: 10.1038/s41467-018-04355-w.

Supplemental Content

Loading ...
Support Center